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Abstract
Background: Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current
treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor
groove of DNA inducing single- and double-strand-breaks. These kinds of damage lead to the activation of PARP1, a
first-line enzyme in DNA-damage response pathways. We hypothesized that PARP1 targeting could perpetuate
trabectedin-induced DNA damage in tumor cells leading finally to cell death.
Methods: We investigated trabectedin and PARP1 inhibitor synergism in several tumor histotypes both in vitro and in
vivo (subcutaneous and orthotopic tumor xenografts in mice). We searched for key determinants of drug synergism by
comparative genomic hybridization (aCGH) and gene expression profiling (GEP) and validated their functional role.
Results: Trabectedin activated PARP1 enzyme and the combination with PARP1 inhibitors potentiated DNA damage,
cell cycle arrest at G2/M checkpoint and apoptosis, if compared to single agents. Olaparib was the most active PARP1
inhibitor to combine with trabectedin and we confirmed the antitumor and antimetastatic activity of trabectedin/
olaparib combination in mice models. However, we observed different degree of trabectedin/olaparib synergism among
different cell lines. Namely, in DMR leiomyosarcoma models the combination was significantly more active than single
agents, while in SJSA-1 osteosarcoma models no further advantage was obtained if compared to trabectedin alone.
aCGH and GEP revealed that key components of DNA-repair pathways were involved in trabectedin/olaparib synergism.
In particular, PARP1 expression dictated the degree of the synergism. Indeed, trabectedin/olaparib synergism was
increased after PARP1 overexpression and reduced after PARP1 silencing.
Conclusions: PARP1 inhibition potentiated trabectedin activity in a PARP1-dependent manner and PARP1 expression in
tumor cells might be a useful predictive biomarker that deserves clinical evaluation.
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Background
An attractive strategy to improve current treatment op-
tions is to inflict cytotoxic DNA damage with chemother-
apy, and then impede DNA repair by molecular targeting.
Poly-ADP-ribosyl-transferase-1 (PARP1) is a key sensor of
DNA damage and initiates recruitment of the DNA-repair
machinery to the site of damage [1–3]. The development
of PARP1 inhibitors has drawn closer the goal of combin-
ing these compounds with current therapies [2, 4–9]. Un-
fortunately, despite several preclinical data confirming an
increased antitumor activity by combining PARP1 inhibi-
tors with either chemotherapy or radiotherapy [10–16],
dose escalation in phase 1 combination studies has been
greatly hampered by the observed hematologic toxicities.
These adverse events limited the possibility to exploit these
combinations into clinical practice [4, 5, 9, 11, 17–27]. As
a consequence, PARP1 inhibitors are today registered as
monotherapy in cancers bearing DNA-repair deficiencies
[28–34] and the strong rational to combine selected cyto-
toxics (especially alkylators) with PARP1 inhibitors has to
face the risk of myelotoxicity.
Among chemotherapeutics, trabectedin has some
peculiarities that point out this drug as an ideal candi-
date to be combined with PARP1 inhibitors: its favorable
safety profile on the hematologic side and its unique
mechanism of action [35, 36]. In particular, trabectedin
traps enzymes belonging to the transcription-coupled
nucleotide excision repair (TC-NER) system that in the
attempt to remove trabectedin adducts, generates DNA
single- and double-strand breaks. Understandably, tra-
bectedin displays a greater clinical benefit in BRCA1/2-
deficient tumors than in proficient ones [37, 38]. These
characteristics prompted us to explore the combination
of trabectedin and PARP1 inhibitors taking advantage of
a large set of bone and soft tissue sarcoma (BSTS) cell
lines. Despite a common mesenchymal origin, BSTS are
characterized by a great degree of heterogeneity and, in-
deed, trabectedin displays a spectrum of activity in vari-
ous sarcoma histotypes [39–41]. This heterogeneity
allowed us to test cells with different intrinsic sensitivity
to trabectedin, in order to explore if trabectedin could
efficiently activate PARP1, and if PARP1-specific inhib-
ition could be exploited sufficiently to cause irreversible
DNA damage, and eventually tumor cell death. The ob-
served results were subsequently validated in other
tumor types and by combining PARP1 inhibitors with
other cytotoxics characterized by different mechanisms
of action.
Methods
Cell line characterization, cell viability and western blot
Cell lines characteristics are depicted in Additional file 1:
Table S1 and S2. Short tandem repeat (STR) profile was
checked and the genomic status of DNA-repair key
components (BRCA1, BRCA2, ATM, CHEK2, PTEN) was
analyzed by Multiplex ligation-dependent probe amplifica-
tion (MLPA) and Denaturing high performance liquid
chromatography (DHPLC, Wave 3500HT DNA Fragment
Analysis System, Transgenomic Inc.) followed by direct
sequencing (ABI PRISM3100 DNA Sequencer, Applied
Biosystem, Forster City, CA). PARP1, RAD51, and BRCA1
copy number variations was confirmed by real-time poly-
merase chain reaction (PCR) on genomic DNA (TaqMan
Assay, ABI PRISM 7900HT System, Applied Biosystem).
In order to evaluate the proliferation rate of each cell
line, cells were seeded at a density of 2 × 104 cells/cm2,
and the doubling-time (DT) of the harvested cells was cal-
culated during the exponential growth phase (48 h of cul-
ture) by using the algorithm provided by http://
www.doubling-time.com/compute.php: DT = t x lg2/(lgNt
- lgN0) where N0 is the initial concentration of cells, Nt is
final concentration of cells and t is the culture time in
hours. Cell viability was determined with Cell Titer-Glo
(Promega) after 72-h treatment with scalar doses (2–0.125
nM) of trabectedin (PharmaMar), as single agent or in
constant combination with olaparib (20–1.25 μM) or veli-
parib (80–5 μM) (Sequoia research products). These
ranges of concentrations were chosen on the results of
previous studies testing the sensitivity to each single agent
in sarcoma and non-sarcoma cell lines [42–45]. Protein
extracts were obtained after 24-h treatment and resolved
by western blot using primary antibodies from Cell Signal-
ing Technology except for anti- poly(ADP-ribose) (PAR,
Trevigen), phospho-histone H2AX (Ser139) (Millipore).
Quantitative real-time polymerase chain reaction (PCR),
gene expression profiling and Gene Signature enrichment
analysis (GSEA)
2.5 × 106 cells were plated in 150 mm diameter and grown
for 24 h in complete medium. Cells were then treated for
additional 24 h with trabectedin (0.125 nM) and olaparib
(1.25 μM) as single agent and in combination. In each
condition, 500.000 cells were fixed in 70% ethanol for cell
cycle analysis and the remaining fraction was lysed with
Qiazol reagent (Qiagen) for RNA extraction by means of
RNeasy Kit (Qiagen) following manufacturer’s instruc-
tions. Gene expression profiling was performed with
Human HT-12 v4.0 Expression BeadChip Kit (Illumina)
Real-time PCR was performed by TaqMan Gene Expres-
sion Assay using ABI PRISM 7900HT System (Applied
Biosystem). Fluorescence data were automatically con-
verted into CT (cycle threshold) values. To export data,
the threshold was 0.20. Raw data were analyzed by
Microsoft Office Excel. Additional file 2: Figure S1 out-
lined the design of the expression profile project analyzed
by GSEA (http://www.broadinstitute.org/gsea/msigdb/
index.jsp) [46]. To highlight gene patterns associated and
involved with trabectedin and olaparib synergism, we
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designed a specific expression profile project comparing
cell lines displaying high synergism (HS-C: TC-106,
402.91, DMR) and cell lines displaying low/no syner-
gism (LS-C: SJSA-1, HT1080, SW684). First, we com-
pared gene expression profiles of HS-C and LS-C by
GSEA to identify gene sets associated with high syner-
gism. Then we selected the cores of the emerging gene
sets matching the criterion of false discovery rate
(FDR) < 0.05 and we challenged them with GSEA com-
paring each treated HS-C against untreated. GSEA ana-
lysis was performed with default parameters. Probes
were collapsed into gene symbols. Gene set size for
inclusion was set between 15 and 500, and the genes
were permutated 1,000 times. Gene sets that met the
FDR < 0.05 were considered significant. The catalog of
gene sets was downloaded from Molecular Signature
Database (C2, C5, C6, Hallmarks, MSigDB, version 5.0,
http://www.broadinstitute.org/gsea/msigdb/index.jsp) for
a total of 4965 curated gene sets.
Array comparative genomic hybridization (aCGH) analysis
Comparative genomic hybridization using aCGH micro-
arrays was carried out using the enzymatic labeling
method. Digestion, labeling, hybridization, washing and
slide scanning were performed following the manufac-
turer protocols (Agilent Technologies). Briefly, 750 ng of
samples and control DNA in a total volume of 10.1 μL
were digested with restriction enzymes and labeled with
Cy3 and Cy5. Subsequently, labeled DNA was cleaned
up and hybridized using the Agilent-030587 CCMC
CGH plus SNP 180 k Microarray platform. Each test
DNA sample (Cy5) was hybridized with a reference
DNA (Cy3) from Homo sapiens (Agilent). After
hybridization for 24 h at 20 rpm and 65 °C, slides were
washed following Agilent procedure and scanned with
the dual-laser microarray scanner version C (G2505C,
Agilent Technologies). Images were analyzed using
Feature Extraction software version 10.7 (Agilent Tech-
nologies). Raw data were processed using the Agilent
Genomic Workbench version 7. Aberrant regions were
detected using ADM-2 algorithm with threshold = 6. To
avoid false positive calls, the minimum number of con-
secutive probes for amplifications/deletions was set to 3,
together with a minimum average absolute Log Ratio for
aberrations > = 0.25.
Gene ontology (GO) enrichment analysis
Genes mapped in the regions with differential aberra-
tions between HS-C and LS-C were uploaded into
DAVID bioinformatics tool for functional enrichment
analysis and GO biological processes (level 5). Enrich-
ment p-values less than 0.01 were considered as sta-
tistically significant.
Mice xenograft models
Nonobese diabetic/severe combined immunodeficient
(NOD/SCID) mice (Charles River) were injected with: a)
1–2.5 × 106 SJSA-1 subcutaneously (s.c.) into the right
flank or 105 SJSA-1 intravenously (i.v.) into the tail vein
to originate subcutaneous primary tumors and lung me-
tastases, respectively, or b) 106 DMR s.c. or 4 × 105
DMR orthotopically into the uterine wall by laparotomy.
Six mice per group (DMR s.c. model) were randomized
to receive: a) 25 or b) 50 mg/kg/day intraperitoneal (i.p)
injection of olaparib (5 days/week); c) 0.150 or d) 0.1 or
e) 0.05 mg/kg weekly i.v. injection of trabectedin; f )
combination of 25 mg/kg/day olaparib and 0.050 mg/kg
trabectedin or g) left untreated for 21 days and then
sacrificed for histological and molecular assays. SJSA-
1 s.c. models were treated with a) 0.05 mg/kg or b)
0.025 mg/kg weekly i.v. injection of trabectedin; c)
25 mg/kg olaparib i.p; d) combination of 25 mg/kg/day
olaparib and 0.050 mg/kg trabectedin; e) combination of
25 mg/kg/day olaparib and 0.025 mg/kg trabectedin or
g) left untreated for 17 days. DMR orthotopic model was
treated with 0.050 mg/kg trabectedin and 25 mg/kg/day
olaparib as single agent, in combination, or left un-
treated. These in vivo experiments were conducted in
accordance with the protocol approved by the Institu-
tional Ethics Review Board (IRB) and by the Italian
Ministry of Health (Aut. Min. 178/201S-PR). For in vivo
imaging, each mouse received an intra-peritoneal dose
of 150 mg luciferin/kg body weight, and ventral and dor-
sal images were obtained by IVIS Lumina II and quanti-
fied using Living Image software (PerkinElmer).
Flow cytometry assays: cell cycle, P-H2AX, and apoptosis
analysis
The effects of trabectedin and olaparib on the cell cycle
and the expression of the DNA-damage marker P-H2AX
were determined by staining DNA content with propi-
dium iodide (PI, Sigma Aldrich) and FITC-conjugated
primary antibody anti-P-H2AX (Ser139) (Millipore),
respectively, after treatment with trabectedin (0.125 nM)
as single agent or in combination with olaparib (1.25 μM)
for 24 h.
For apoptosis evaluation, after 96-h treatment APC-
labelled Annexin V (eBioscence) and PI (0.5 μg/ml) stain-
ing was done. All samples were acquired by Cyan ADP
Flow cytometer (Beckman Coulter) and analyzed by the
Summit v4.3 (Dako) and FlowJo (Tree Star) softwares.
Comet assay (Single Cell Gel Electrophoresis assay)
For determination of DNA single- and double-strand
breaks, a single-cell gel electrophoresis assay was used
(Comet Assay TM, Trevigen) per the manufacturer’s
instructions after 48-h treatment with trabectedin
(0.125 nM) and olaparib (1.25 μM), as single agents
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or in combination. Quantization of the DNA in the
tails of the comets was performed with Quantity One
software (Bio-Rad Laboratories) and ImageJ software
version 1.49 (http://rsbweb.nih.gov/ij/index.html).
Lentiviral vector production
pCCL.sin.cPPT.polyA.CTE.eGFP.minhCMV.hPGK.Lucifer
ase.Wprep or lentiviral plasmid vector PLKO-puro
(Sigma-Aldrich), the Precision LentiORF PARP1 (Id:P
LOHS_100004266, Thermo Scientific) and packaging vec-
tors pMDLg/pRRE pRSV-REV and pMD2.VSVG were
used for lentiviral preparation. Efficiency of transduction
was confirmed by western blot analysis and flow cytome-
try analysis by Cyan ADP Flow cytometer (Beckman
Coulter). The luciferase activity was tested by in vitro bio-
luminescent assay (Caliper Life Sciences, Inc.) and mea-
sured by IVIS Lumina II (PerkinElmer).
Archival tumor samples, immunostaining, and terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay
Archival formalin-fixed, paraffin-embedded (FFPE)
tumor samples were collected in accordance with an IRB
approved protocol (202/2014). Four μm slices were cut
and stained with primary antibodies against PARP1,
BRCA1 and RAD51 (Abcam) following standard immu-
nohistochemistry procedure. The same antibodies and
one antibody against PAR (Calbiochem) were used for
immunocytochemistry on cells grown as monolayer in
chamber slides. TUNEL assays were used to evaluate the
number of apoptotic cells in tumors explanted from
mice, using the ApopTag kit (Millipore). Immunostain-
ing on mice xenografts was performed according to
standard protocols with primary antibodies from Sigma
Aldrich (proliferating cell nuclear antigen, PCNA),
Abcam (p-H2AX Serine 139). Nuclei were counter-
stained with hematoxylin. Immunofluorescence was
done with FITC-conjugated antibody against P-H2AX
(Millipore). Nuclei were counterstained with DAPI.
Fluorescence in situ hybridization (FISH) analysis of
PARP1 and centromeres was performed following stand-
ard procedures.
Visible images were acquired with a Leica DM1000
microscope equipped with a color 3.1 M Pixel CMOS
digital camera. Fluorescent images were acquired with a
Leica confocal laser-scanning microscope (TCS SP5
AOBS). For signal quantification, 5 images/sample were
acquired by maintaining constant parameters. Image
quantification was performed using ImageJ software and
Leica Confocal Software.
Statistical and pharmacological combination analyses
All in vitro experiments were performed at least three
times. Differences between treatment groups were
analyzed by the two-tailed Student’s t test and the two-
way ANOVA with post hoc Bonferroni’s correction for
multiple tests using GraphPad Prism 5 (GraphPad Soft-
ware Inc.). The concentration inhibiting 50% of the cell
growth (IC50) with its 95% confidence intervals (95%
CI), and drug synergism, expressed as combination
index (CI) calculated at IC50 with its estimated standard
deviation were obtained by using CalcuSyn software
(Biosoft). The correlation analyses between ΔCT values
(mRNA levels) or protein expression levels and combin-
ation indexes were performed by calculating Pearson
correlation coefficient, t-distribution, and P values by
Microsoft Excel.
Results
Trabectedin and olaparib synergism is related to PARP1
expression
Initially, we demonstrated that in bone and soft tissue sar-
coma (BSTS) cell lines trabectedin treatment significantly
increased phosphorylated histone H2AX (P-H2AX), the
marker of DNA double-strand breaks (p < 0.001,
Fig. 1a-c). Subsequently, we showed that after 24-h
treatment with the combination of trabectedin (0.125
nM) and olaparib (1.25 μM) there was a variable but
significant increase in P-H2AX positive cells if compared
to single agents and untreated controls (Fig. 1a-c). There-
after, we studied the role of PARP1 enzymatic activity
(PARylation) after 4-h treatment with trabectedin (10 nM).
We observed that in 3/6 (50%) bone and soft tissue
sarcoma (BSTS) cell lines PARylation was highly increased,
as compared to untreated controls (Fig. 1d). In these cells,
the PARP1 inhibitor olaparib inhibited both basal and
trabectedin-induced PARP1 activation remarkably well
(Fig. 1d). To elucidate why trabectedin failed to activate
PARP1 equally in all cell lines, we studied the correlation
between PARP1 basal expression, activity and gene sta-
tus. We found that after trabectedin exposure, PARyla-
tion was significantly increased in high- vs. low-PARP1-
expressing cells (Fig. 1d). To further explain differences
in PARylation activity, we performed mutational ana-
lysis of PARP1 gene and we found the Val762Ala single
nucleotide polymorphism in SJSA-1 and SW684 cells
(Additional file 2: Figure S2).
These results caused us to explore the effect of PARP1
inhibition on trabectedin-induced DNA damage and we
found that 24-h treatment with the combination of
trabectedin (0.125 nM) and olaparib (1.25 μM) signifi-
cantly increased P-H2AX signaling in all cell lines
tested (p < 0.001, Fig. 1a-c) if compared to both single
agents and controls. Irreparable DNA fragmentation
was significantly increased after 48-h treatment with
the combination if compared to both single agents and
controls in high-PARP1-expressing cells, as shown by
COMET assay (p < 0.001; Fig. 1e-f ). On the contrary, in
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low-PARP1-expressing cells, P-H2AX activation led to
DNA repair. The intensity of the combination-induced
DNA damage caused a cell line-dependent cell cycle ar-
rest at G2/M checkpoint and the accumulation of cells
into the late S phase (Fig. 2a), resulting in apoptosis
after 96 h (Fig. 2b). This effect was consistently stron-
ger in high-PARP1-expressing cells (TC-106, DMR,
402.91) and led to a significant inhibition of tumor cell
colony growth (p < 0.001; Fig. 2c-d).
To expand our findings, we tested the antitumor activ-
ity of serial dilutions of two PARP1 inhibitors, olaparib
(20–1.25 μM) and veliparib (80–5 μM) in a panel of 20
different BSTS cell lines, both as single agents and in
constant combination with serial dilution of trabectedin
(2–0.125 nM). We observed a strong synergism of
trabectedin + olaparib in 18/20 cell lines while in the
trabectedin + veliparib combination, we observed less
synergism in 15/19 cell lines (Fig. 2e, Additional file 1:
Table S1). In high-PARP1-expressing cells the trabecte-
din IC50s were significantly reduced if compared to low-
PARP1-expressing cells both in combination with
olaparib and veliparib (p = 0.01 and p = 0.02, respectively;
Additional file 2: Figure S3).
Based on these in vitro experiments, we chose ola-
parib and trabectedin for further drug combination
studies. As an example, Additional file 2: Figure S4
shows dose-effect curves obtained in TC-106, 402.91, DMR;
SJSA-1, HT1080, and SW694 cells. Synergy was distributed
along a spectrum of intensity; it was strongest in Ewing’s
sarcoma cells and decreased progressively from liposarcoma
(myxoid > dedifferentiated) to osteosarcoma to undifferenti-
ated pleomorphic sarcoma to fibrosarcoma (Fig. 2e,
Additional file 1: Table S1). Of note is that the doxorubicin-
resistant leiomyosarcoma cell line MES-SA-DX5 also dis-
played cross-resistance to trabectedin, but addition of
PARP1 inhibitors restored sensitivity to a clinically achiev-
able trabectedin concentration (Additional file 1: Table S1
and Additional file 2: Figure S2e). Interestingly, MES-SA-
DX5 cells displayed higher basal PARP1 expression and
activity (Additional file 2: Figure S5 if compared with their
parental counterparts, due to PARP1 gene amplification as
shown by fluorescent in situ hybridization (FISH, Additional
file 2: Figure S5 and Additional file 1: Table S4), real- time
PCR (Additional file 1: Table S5), and by array comparative
genomic hybridization (aCGH) analysis (https://www.ncb
i.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77175).
Fig. 1 Olaparib enhanced trabectedin-induced DNA damage in high-PARP1-expressing cells. FACS analysis of P-H2AX positive cells after 24-h treatment
with 0.125 nM trabectedin, 1.25 μM olaparib as single agents and in combination: a representative histograms of DMR cells and b mean quantification of
P-H2AX in TC-106 (Ewing), 402.91 (liposarcoma), DMR (leiomyosarcoma), SJSA-1 (osteosarcoma), and HT1080 and SW684 (fibrosarcoma) cells; Y error bars
indicate mean ± S.E.M;*** p< 0.001 between combination and both single agents and controls. c Immunofluorescence of P-H2AX in DMR cells treated as
in (a and b); d Western blot analysis of PARP1 activity (PARylation) and PARP1 expression after 4-h treatment with 10 nM trabectedin, 20 μM olaparib as
single agents and in combination; β-actin was done as loading control; e-f DNA fragmentation obtained after 48-h treatment with 0.125 nM trabectedin,
1.25 μM olaparib as single agents and in combination as revealed by COMET assay: E, representative photomicrographs of COMET tails in 402.91 cells;
f Box-plot shows mean comet eccentricity ±25% (boxes) and the 5–95% percentile (whiskers)
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Cell cycle control and DNA-repair pathways are involved
in the activity of trabectedin and olaparib combination
To dissect the molecular mechanism behind trabecte-
din + olaparib synergism, we compared the gene expres-
sion profiles (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE76981) of three cell lines with high
synergism (HS-C) and three cell lines with low/no
synergism (LS-C). First, we compared gene expression
profiles of HS-C and LS-C by gene set enrichment
analysis (GSEA) to identify gene sets associated with the
sensitive phenotype and we found 437 gene sets matching
the criteria of false discovery rate (FDR) <0.05 and we
challenged them with GSEA, comparing each treated cells
against untreated. Of these ones, 57 gene sets were specif-
ically enriched in combination treatment in HS-C, but not
in single treatments. Of note, the expression of specific
gene sets involved in DNA-damage response, DNA-repair
pathways, and cell cycle control were higher in HS-C than
in LS-C (Fig. 3a). Notably, these gene sets were specifically
down-modulated by the drug combination-not by single
agents- in HS-C, but were either unmodified or upregu-
lated in LS-C (Fig. 3a). Taken together, these results indi-
cated that specific gene sets involved in the DNA-damage
response, G2/M cell cycle checkpoint, and DNA-repair
pathways were implicated in the mechanisms behind
trabectedin/olaparib synergism.
Consistent evidences were shown also by comparing
genomic profiles of HS-C and LS-C as obtained by aCGH
(Additional file 2: Figure S6, Additional file 3 and https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77175).
Fig. 2 The synergistic antitumor activity of trabectedin and PARP inhibitors was cell line-dependent. FACS analysis of (a), DNA content (cell cycle distribution)
after 48-h treatment with 0.125 nM trabectedin and 1.25 μM olaparib alone and their combination, green, yellow, and light blue represent G0/G1, S phase, and
G2/M phase, respectively; as calculated by Flow Jo software; b apoptosis (Annexin V-PI staining) obtained after 72-h treatment with 0.125 nM trabectedin and
1.25 μM olaparib alone and their combination; c representative 7-day colony growth assay with 402.91 and SJSA-1 cells testing 0.125 nM trabectedin, 1.25 μM
olaparib and their combination; d quantitation of three independent experiments of colony growth with 402.91 and SJSA-1 cells testing trabectedin, olaparib
and their combination. e IC50 distribution of trabectedin as a single agent and in combination with olaparib or veliparib obtained by Calcusyn software after
72-h treatment with serial dilution of trabectedin (2–0.125 nM), olaparib (20–1.25 μM), veliparib (80–5 μM) as single agents or in constant combination with
trabectedin, dashed lines indicate median IC50. Y error bars indicate mean± S.E.M;*** p< 0.001 between combination and both single agents and controls
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Differential aberration analysis demonstrated four groups
of genomic alterations that clearly distinguished HS-C
from LS-C (Additional file 3). Namely, regions of chro-
mosomes enriched in genes involved in DNA-damage
response/repair and G2/M cell cycle checkpoint were
deleted and amplified in HS- and LS-cells, respectively (as
highlighted in Additional file 3).
To validate these findings, we confirmed the genomic
status of selected genes (Additional file 1: Table S4-S6)
with different approaches (FISH, real-time PCR on
genomic DNA, multiplex ligation-dependent probes
amplification, denaturing high performance liquid chro-
matography, and sequencing) and analyzed expression
of DNA-damage response/repair pathways key compo-
nents in 19 cell lines using quantitative real-time PCR
(Additional file 1: Table S3). Our results show that
mRNA expression of PARP1, RAD51, and BRCA1 (but
not their genomic status) is directly related to combin-
ation synergism (Fig. 3b, Additional file 1: Table S2-S5).
Furthermore, in selected experiments, we confirmed these
data at protein level by western blot and immunocyto-
chemistry, and demonstrated that the expression of
PARP1, BRCA1, and RAD51 was higher in HS-C than in
LS-C (Fig. 3c-d).
Next, we evaluated the expression of these putative
biomarkers in patients who might benefit from trabecte-
din + olaparib treatment. We employed immunohisto-
chemistry (IHC) to measure PARP1, BRCA1, and RAD51
expression in a panel of 54 patient-derived sarcoma speci-
mens. PARP1, BRCA1, and RAD51 were overexpressed in
34/53 (64%), 18/54 (33%), and 35/54 (65%) samples,
respectively (Fig. 4, Additional file 1: Table S7). For all,
IHC expression was characterized by high concordance
rates (Additional file 1: Table S8) with an 85% (95% CI:
Fig. 3 PARP1, RAD51, and BRCA1 expression and gene signatures as predictive markers of trabectedin and olaparib synergism. a, enrichment
analysis of gene sets (GSEA) published in Molecular Signatures Database v5.0 of Broad Institute obtained by comparing mRNA expression profiles
in cells displaying high combination synergism (HS-C: TC-106; DMR; 402.91) with cells displaying low/no synergy (LS-C: SJSA-1; HT1080; SW684) at
basal condition (untreated) or after 24-h treatment with 1.25 nM trabectedin (TR), 1.25 μM olaparib (OL), or combination (CB); b, direct correlation
(linear regression) between synergism of trabectedin and olaparib in combination (combination index) and mRNA expression (ΔCT) of PARP1,
BRCA1, and RAD51 in 19 human sarcoma cell lines (as in Additional file 1: Table S3); Pearson score r and P value are indicated in blue, red and
green for PARP1, BRCA1 and RAD51 respectively; c, western blot analysis and D, immunocytochemistry of PARP1, BRCA1, and RAD51 expression in
TC-106, DMR, 402.91, SJSA-1, HT1080, and SW684
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73–97%) and 86% (95% CI: 75–97%) probability of finding
PARP1 overexpressed in BRCA1- and RAD51-positive
samples, respectively.
Antitumor activity of trabectedin and olaparib
combination in HS-C and LS-C mice models
Thereafter, we studied in vivo antitumor activity of the
combination. We subcutaneously injected (s.c.) one
tumorigenic HS-C (DMR) and one LS-C (SJSA-1) in
nonobese diabetic/sever combined immunodeficient
(NOD/SCID) mice. Mice with tumors ≥32 mm3 were
randomized to receive drug treatment.
In DMR s.c. model, mean tumor volume was signifi-
cantly reduced by the treatment with two doses of trabec-
tedin (0.15 and 0.1 mg/kg, p < 0.0001) and not by the
lowest dose (0.05 mg/kg; ns, non-significant, p > 0.05).
Olaparib as single agent (two doses, 50 and 25 mg/kg/day)
did not show antitumor activity. Interestingly, the combin-
ation of trabectedin and olaparib at the lowest concentra-
tions (25 mg/kg/day olaparib + 0.05 mg/kg trabectedin)
significantly reduced tumor growth if compared to un-
treated controls and each single agent (Fig. 5a). In SJSA-
1 s.c. models the treatment with 0.05 mg/kg of trabectedin
significantly reduced tumor growth and no further advan-
tage was obtained by the combination with 25 mg/kg/day
of olaparib (ns, p > 0.05) (Fig. 5b). At the lowest dosage
(0.025 mg/kg) trabectedin did not impinge tumor growth
both as single agent and in combination with olaparib
25 mg/kg (Fig. 5b). Tumor cell proliferation was evaluated
by PCNA staining (Fig. 5c), DNA damage by P-H2Ax foci
formation and apoptosis by TUNEL staining in
combination-treated mice and compared to both controls
and single agents (0.05 mg/kg trabectedin and 25 mg/kg
olaparib). In DMR s.c. models, cell proliferation was sig-
nificantly reduced (PCNA, Fig. 5c), and consistently both
DNA damage (P-H2AX, Fig. 5c) and apoptosis (TUNEL,
Fig. 5c) were significantly increased by the combination if
compared to single agents and controls. Evaluation of the
same parameters in LS-C SJSA-1 xenografts showed that
trabectedin was effective as single agent, and only a
marginal advantage was obtained by the combination
(Fig. 5c-d). The combination of trabectedin and olaparib
did not cause evident signs of toxicity after gross necropsy
or weight loss during treatment.
To assess combination activity in the metastatic set-
ting, we developed an orthotopic model of uterine leio-
myosarcoma with HS-C DMR cells and an experimental
metastatic model of osteosarcoma with LS-C SJSA-1
cells. DMR cells injected into uterine wall tissue devel-
oped local and distant metastases within 3 weeks in the
untreated control group. Treatment with single agents
delayed, but did not impede, tumor progression, whereas
trabectedin + olaparib not only significantly reduced pri-
mary tumor growth, but also prevented metastatic
spread (p < 0.001 vs. single agents and control; Fig. 5e-f ).
On the contrary, in the metastatic osteosarcoma model,
the combination showed non-significant advantage over
trabectedin alone (p > 0.05) (Fig. 5g-h). These in vivo ex-
periments confirm data observed in vitro, wherein low-
PARP1-expressing cells consistently demonstrated lower
synergy of the combination.
PARP1 expression dictates the response to trabectedin
and olaparib combination
To generalize to other tumor settings our observations
on PARP1 inhibition, we tested trabectedin + olaparib
Fig. 4 Representative immunohistochemical analysis and relative Intensity Scores (0, +, ++) of PARP1, BRCA1, and RAD51 expression in patient-
derived sarcoma specimens
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activity in an independent panel of 11 tumor cell lines
of different origins (prostate, lung, bile duct, breast),
and verified a direct correlation between PARP1 protein
expression and combination synergy (Fig. 6a, Additional
file 1: Table S2). Finally, the functional role of PARP1 to
determine trabectedin + olaparib synergy was further
proved in silencing and overexpression experiments.
Namely, PARP1 expression was downregulated with
specific transient and stable silencing (Fig. 6b) in two
HS-C (TC-106, 402.91), which resulted in significantly
reduced trabectedin + olaparib activity compared to
mock-treated cells (p < 0.001; Fig. 6c). On the other
hand, the overexpression of PARP1, determined by
stable lentiviral transduction (Fig. 6b) in two LS-C
(SJSA-1, SW684), consistently and significantly in-
creased combination activity vs. mock-treated controls
(p < 0.001; Fig. 6d). Indeed, activity rose to levels ob-
served in HS-C (Fig. 6c-d).
PARP1 expression determines the cellular response to
different DNA-damaging agents
Finally, to generalize the key role played by PARP1 basal
expression in synergism, we asked whether enzyme basal
expression might drive tumor cell response to other
cytotoxics used in combination with PARP1 inhibitors.
We investigated PARylation in both low- vs. high-
PARP1-expressing cells and PARP1-silenced vs. wild-
type counterparts (Additional file 2: Figure S7A) after
the treatment with different chemotherapeutic agents:
cisplatin, dacarbazine, actinomycin-D, etoposide, doxo-
rubicin, and gemcitabine characterized by different
mechanism of action: crosslinking, methylation, tran-
scription inhibition, topoisomerase II inhibition, DNA
intercalation, and nucleotide mimicking, respectively.
Consistently with trabectedin experiments, we found
that PARylation correlated directly with PARP1 basal
expression (higher in high- vs. low-PARP1-expressing
Fig. 5 Trabectedin and olaparib combination showed antitumor effects in in vivo models. a-b, Tumor volume and c-d, histological analysis of
proliferating cells (PCNA staining), DNA damage (P-H2AX), and apoptosis (TUNEL) in DMR and SJSA-1 s.c. xenografted NOD/SCID mice treated
with trabectedin and olaparib, as single agent and in combination or untreated. e-f, in vivo imaging of tumor growth and spread in orthotopic
uterine leiomyosarcoma model and g-h, tumor colony growth in e.v. SJSA xenografted NOD/SCID mice treated with trabectedin and olaparib as
single agents and in combination, or left untreated; in vivo imaging was done 3 days after the end of the 21-day- treatment; Y error bars indicate
mean ± S.E.M; *p < 0.05; **p < 0.01; *** p < 0.001
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cells), regardless of the studied cytotoxic or its mechanism
of action (Additional file 2: Figure S7B). Indeed, in
MSTO-H211 parental cells cisplatin, etoposide, gemcita-
bine and trabectedin were potent activator of PARP1 activ-
ity, while doxorubicin, actinomycin-D and dacarbazine (as
pro-drug) less efficiently induced PAR (Additional file 2:
Figure S7B). After PARP1 silencing in MSTO-H211 cells,
PARylation was invariably decreased if compared to paren-
tal cells after each treatment.
Discussion
We identified and demonstrated that PARP1 basal expres-
sion is crucial in the mechanism behind the synergy
between PARP1 inhibitors and trabectedin independent of
BRCA1/2 status, in several robust models across different
histotypes. The chemo-sensitization observed in high-
PARP1-expressing cells suggests that PARP1 inhibitors may
extend and improve the clinical application of DNA-repair
targeting when combined with other cytotoxics also.
Our findings support a reappraisal of PARP1 inhibitors
as chemo-sensitizers. In general, after chemotherapy
exposure, tumor cell fate is highly dependent on the effi-
ciency of the same DNA-damage response pathways that
restore normal cell DNA integrity. This observation
fueled the idea to target key points in DNA-repair ma-
chinery to increase cytotoxicity [2, 4] and brought about
the development of several compounds, among which
PARP1 inhibitors eventually demonstrated clinical effi-
cacy [4]. However, so far, their clinical use is limited to
tumors harboring hereditary or acquired genetic defects
in homologous recombination (HR) exploiting an intrin-
sic cell weakness through so-called “synthetic lethality”
[28–34]. Interestingly, patients affected by HR-defective
tumors have the greatest benefit from treatment with
DNA-damaging agents, such as platinum compounds
and trabectedin [37, 38, 47].
We pursued to induce a sort of “chemical synthetic
lethality” also in HR-proficient tumors, by combining
Fig. 6 a direct correlation (linear regression) between drug synergism of trabectedin and olaparib in combination (1 - combination index) and PARP1
protein expression (western blot image quantitation) in 11 human tumor cell lines with different origin (Additional file 1: Table S2); Pearson score r and
P value are indicated; b western blot analysis of PARP1 and actin (as housekeeping) protein expression in cells stably transduced with lentiviral vector
carrying PARP1 specific shRNA for silencing or functional PARP1 gene for overexpression; c cell viability assay in PARP1 stably silenced (shPARP1) HS-C
TC-106 and 402.91 cells and their parental wild type (wt) counterparts; d cell viability assay in LS-C (SJSA-1 and SW684) overexpressing PARP1 (over-
PARP1) and their parental wild type (wt), Y error bars indicate mean ± S.E.M; *** p < 0.001 between combination and both single agents and controls
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trabectedin with PARP1inhibitors. Our hypothesis
stemmed from the observation that trabectedin not only
induced a peculiar DNA damage but also caused impair-
ment in the DNA-repair machinery that might become
lethal in presence of PARP1 inhibitors [35].
Demonstration that trabectedin strongly activates PARP1
enzyme strengthened our idea to combine this chemother-
apy with PARP1 inhibitors. However, after trabectedin
treatment, we observed significantly different PARylation
across various histotypes. For example, single nucleotide
polymorphism in the PARP1 gene (Val762Ala) is known to
result in a less efficient PARP1 variant [48, 49], which may
partly explain differences in the degree of PARylation. To
understand the impact of PARylation differences, we
turned to PARP1 basal expression and proved that PARP1
protein basal level was not only directly proportional to
chemotherapy-induced PARP1 activation, but also that it
dictated the synergism with trabectedin and several other
chemotherapy compounds as well. Indeed, PARP1-
depleted cells were tolerant to PARP1 inhibitors [50, 51],
and therefore, PARP1 activity is the prerequisite to induce
a significant amount of complexes formed by PARP1,
damaged DNA and PARP1 inhibitor that are plausibly
more cytotoxic than unrepaired single-strand breaks alone
[52–54]. Clearly, trabectedin synergized with both tested
PARP1 inhibitors, but we found olaparib was significantly
more potent than veliparib. Our result reflects the fact that
veliparib is a pure catalytic inhibitor of PARP1 activation,
whereas olaparib is a poisoning drug that blocks activated
PARP1 enzyme at the site of damage (PARP1-trapping
activity) impeding the subsequent recruitment of repairing
machinery [11, 52, 55]. We studied the synergism of
PARP1 inhibitors and trabectedin in a large set of different
tumor cell lines and in in vivo models, demonstrating that
PARP1 inhibition improved the antitumor activity of tra-
bectedin in a cell-line dependent intensity, as previously
shown in breast cancer and in Ewing’s sarcoma cell lines
[44, 55]. Among the tested BSTS histotypes, Ewing’s
sarcoma cells were the most sensitive to the combination,
a result that might be explained by the known exquisite
sensitivity of the pathognomonic fusion protein EWS/
FLI1-expressing cells to both trabectedin and PARP1
inhibition [10, 56–59].
Another important datum emerged from study of the
MES-SA-DX5 model. This leiomyosarcoma cell line
had been previously made resistant to doxorubicin [60],
and interestingly, we found it also shared cross-
resistance to trabectedin. Of note is that the addition of
PARP1 inhibitors restored sensitivity to clinically
achievable concentration of trabectedin. The increased
activity in MES-SA-DX5 can be explained by compar-
ing the genomic and protein status of this cell line with
its parental counterpart. Indeed in MES-SA-DX5, the
PARP1 gene was amplified and consequently caused
higher PARP1 expression and activity that confirmed
the mechanistic role played by PARP1 in determining
synergy between trabectedin and PARP1 inhibitors.
These consistent observations further prove the key
role played by PARP1 expression.
Given the redundant complexity of DNA repair ma-
chinery, we took advantage of gene array analyses to
delve deeper into the mechanisms behind trabectedin +
olaparib synergism. We identified specific gene sets in-
volved in the combination synergism. These genes be-
long to cell cycle control such as normally activated G2/
M cell cycle checkpoints and DNA-damage response
and repair pathways (i.e., Timeless, AURKA, MCM2,
RAD54L, POLD1, MRE11A) [61–64]. Moreover, specific
genomic aberrations of these genes differentially charac-
terized HS-C and LS-C. We showed that enzymes
involved in DNA-damage response and repair were actu-
ally expressed more in cell lines displaying higher PARP1
basal expression and high trabectedin + olaparib syner-
gism. The cell cycle phase is crucial for trabectedin and
olaparib response and these findings confirmed our data
on cell cycle perturbation. Undeniably, trabectedin-
induced DNA damage activates the DNA-damage re-
sponse leading to G2/M cell cycle arrest [35]. However,
in this phase, repairing enzymes may still fix the damage
caused by either single agent, such that tumor cells sur-
vive after initial cell cycle arrest. On the contrary, when
the combination was used, DNA repair and cell survival
were impeded because of irreparable DNA fragmenta-
tion and apoptosis.
Again the intensity of this event directly correlated
with PARP1 expression. We carefully validated the role
of identified candidate genes in two independent panels
of 20 and 11 different cell lines. We selected key en-
zymes of DNA-damage response and repair pathways
and investigated their expression by real-time PCR in
the first 20 BSTS cell-line panel. We confirmed a statis-
tically significant direct correlation between PARP1
expression and trabectedin + olaparib synergism. Inter-
estingly, we also observed a significant correlation be-
tween drug synergism and RAD51 and BRCA1
expression, which might be explained by the fact that in
HR-proficient cells, PARP1 expression drives the tran-
scription of BRCA1 and RAD51 genes co-activating E2F
transcription factor [65–69]. If so, then the statistical
correlation between combination synergism and RAD51
or BRCA1 expression might simply reflect the level of
PARP1 expression. These data are consistent with previ-
ous observations of correlation between DNA repair
protein expression and sensitivity to PARP1 inhibition
[70]. Nonetheless, in HR-defective cells PARP1 activity
was found increased [54]. However, we did not find any
correlation between the genomic status of key DNA re-
pair genes and the synergism of the combination. To
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strengthen our observation and generalize our hypoth-
esis on the role of PARP1 expression also in non-
sarcoma cells, we replicated our experiments in a second
independent panel (11 cell lines of different tumor ori-
gin) and confirmed the correlation between trabectedin
+ olaparib synergy and PARP1 expression also at the
protein level. The functional role of PARP1 was further
validated in silencing and overexpression experiments
that confirmed the data reported above. Noteworthy, the
modulation of PARP1 expression or the inhibition of its
activity might modulate the nuclear factor Kappa-b
pathway that is a crucial determinant of drug resistance
[71–73]. This intriguing aspect warrants further
investigations.
Conclusions
Our data demonstrated that trabectedin is an ideal partner
of PARP1 inhibitors because it potently activates PARP1.
Furthermore, PARP1 basal expression drives the syner-
gism intensity between PARP1 inhibitors and trabectedin.
Indeed, the crucial role of PARP1 expression was con-
firmed in several BSTS histotypes and in other cancer
types as well. Further studies of combinations of PARP1
inhibitors and other cytotoxics should consider basal
PARP1 expression and activation after each drug expos-
ure. Finally, olaparib and trabectedin combination is par-
ticularly attractive in tumors harboring high PARP1
expression and a specific DNA-damage response/repair
and cell cycle control gene signatures that might become
predictive biomarkers of response. Our findings pave the
way for the future clinical study of trabectedin + olaparib
combination independent of BRCA1/2 status.
Additional files
Additional file 1: Table S1. Concentrations inhibiting 50% of cell viability
(IC50) after 72- h treatment with serial dilutions of trabectedin (2–0.125 nM),
olaparib (20–1.25 μM), and veliparib (80–5 μM) as single agents (a) or in
constant combination (b, c), and their 95% confidence intervals (95% CI).
Population doubling time. Combination index ± estimated standard
deviation (est st dev) calculated at IC50 by the Chou-Talalay method for
trabectedin and olaparib in combination and trabectedin and veliparib in
combination in cell lines of different histotypes: leiomyosarcoma (LMS),
undifferentiated pleomorphic sarcoma (UPS), myxoid liposarcoma (LMS),
dedifferentiated liposarcoma (DLS), fibrosarcoma (FSA), synovial sarcoma
(SS), Ewing’s sarcoma (ES), and osteosarcoma (OS). Supplier and culture
conditions are reported for each cell line. Table S2. Direct correlation
between combination index (calculated at IC50) and PARP1 protein intensity
expressed as Pearson score (r Pearson). IC50 and 95% confidence intervals
(95% CI) were calculated after 72-h treatment with serial dilutions of
trabectedin (2–0.125 nM), olaparib (20–1.25μM), and their constant
combination. Cell line characteristics, population doubling time,
purchasers and culture conditions were included. Table S3. Gene
expression (ΔCT) of DNA-damage response and repair key components
and drug synergism expressed by combination index (CI). The correlation
between each gene expression and the CI was evaluated by Pearson score
(r); t distribution and their relative P value were shown. Yellow cells highlight
significant direct correlation. Table S4. PARP1 gene (chromosome 1
q42.12d) copy number obtained by FISH. Table S5. PARP1, BRCA1, RAD51
gene copy number obtained by real- time PCR on genomic DNA. The gene
copy number of PARP1, RAD51, and BRCA1 did not correlate with the
Combination index (CI) as shown by Pearson score. Table S6. Genomic
status of selected genes analyzed by MLPA and DHPLC /Sequencing. Red
cells indicate increased copy number, while blue cells indicate reduced copy
number as obtained by DHPLC analysis. Table S7. Immunohistochemistry
score of intensity for PARP1, BRCA1, and RAD51 protein expression in for-
malin-fixed paraffin-embedded sarcoma samples. Table S8. 2 × 2 con-
tingency tables of immunohistochemistry (IHC) expression of PARP1,
BRCA1, and RAD51 in patient-derived soft tissue and bone sarcoma
specimens (a, b, c) and related concordance rates (d). (DOCX 2086 kb)
Additional file 2: Figure S1. Overview of gene expression analysis.
GSEA, gene signature enrichment analysis. Figure S2. DNA sequences
of single nucleotide polymorphism at codon 762 of PARP1 gene in
HT1080, SJSA-1, and SW684 cells. Figure S3. Distribution of trabectedin
IC50 as single agent (TR alone) and in combination with veliparib (TR +
VEL) or olaparib (TR + OL) among high-PARP1-expressing cells (red
triangle) and low-PARP1-expressing cells (blue triangle). Figure S4.
Dose- response curve obtained after 72-h treatment with trabectedin
(2–0.125nM), olaparib (20–1.25 μM) as single agents and in constant
combination. Figure S5. A, western blot analysis of PARylation and
PARP1 expression in MES-SA and MES-SA-DX5 leiomyosarcoma cells; B,
FISH analysis of PARP1 gene (red) and centromere of chromosome 1
(green) in MESSA and MESSA-DX5. Figure S6. Genomic status as obtained
by aCGH analysis of TC-106, 402.91, DMR, SJSA-1, HT1080, SW684: gain (red)
and loss (green) of chromosome regions. Figure S7. A, Western blot analysis
of PARylation and PARP1 expression and B, quantitation of PAR in MSTO-
H211, and PARP1-silenced MSTO-H211 untreated or treated with 10nM
trabectedin, 20 μM cisplatin (Sandoz), 20 μM gemcitabine (Sandoz), 20 μM
doxorubicin (Pfizer), 20 μM dacarbazine (Medac), 20 μM etoposide (Teva), 50
mM actinomycin-D (Thermo Fisher Scientific), β-actin was done as loading
control. (DOCX 5982 kb)
Additional file 3: Analysis of differential genomic aberrations in HS-C
and LS-C cells. (PDF 255 kb)
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